News - Local News: Towcester and the villages in NN12 (NN12)
AboutMyArea - Local news, events and much more.
Source: aboutmyarea.co.uk
Page 3 - Week Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Week Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Week Data Today - Breaking & Trending Today
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial...
Source: prnewswire.com
AbbVie's Upadacitinib Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
ABBVie today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis showing upadacitinib met the primary endpoint of Assessment in SpondyloArthritis International Society 40 response and the majority of ranked secondary endpoints at week 14. 1 Significantly more upadacitinib-treated patients achieved ASAS40 ...
Source: investingnews.com
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active...
Source: prnewswire.com
AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress - In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2] - The safety results of RINVOQ 15 mg were consistent with previously reported results in rheumatoid arthritis, with no new significant safety risks identified[1],[3] - Full results to be presented at...
Source: prnewswire.com